GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » eFFECTOR Therapeutics Inc (OTCPK:EFTR) » Definitions » Book Value per Share

EFTR (eFFECTOR Therapeutics) Book Value per Share : $0.21 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is eFFECTOR Therapeutics Book Value per Share?

eFFECTOR Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $0.21.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

eFFECTOR Therapeutics's current price is $0.0002. Its book value per share for the quarter that ended in Mar. 2024 was $0.21. Hence, today's PB Ratio of eFFECTOR Therapeutics is 0.00.


eFFECTOR Therapeutics Book Value per Share Historical Data

The historical data trend for eFFECTOR Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

eFFECTOR Therapeutics Book Value per Share Chart

eFFECTOR Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Book Value per Share
-81.89 10.70 2.34 -1.94

eFFECTOR Therapeutics Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.84 1.05 -1.59 -1.94 0.21

Competitive Comparison of eFFECTOR Therapeutics's Book Value per Share

For the Biotechnology subindustry, eFFECTOR Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


eFFECTOR Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, eFFECTOR Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where eFFECTOR Therapeutics's PB Ratio falls into.


;
;

eFFECTOR Therapeutics Book Value per Share Calculation

eFFECTOR Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(-5.80-0.00)/2.98
=-1.94

eFFECTOR Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(0.83-0.00)/3.90
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


eFFECTOR Therapeutics  (OTCPK:EFTR) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


eFFECTOR Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of eFFECTOR Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


eFFECTOR Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
142 North Cedros Avenue, Suite B, Solana Beach, CA, USA, 92075
eFFECTOR Therapeutics Inc is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as selective translation regulator inhibitors (STRIs).
Executives
Sr One Capital Fund I Aggregator Lp 10 percent owner C/O DESIGN THERAPEUTICS, INC., 6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD CA 92011
Christopher B Ehrlich director, 10 percent owner, officer: Chief Executive Officer 499 ILLINOIS STREET, SUITE 200, SAN FRANCISCO CA 94158
Mayank Gandhi officer: Chief Business Officer 628 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Douglas J Warner officer: Chief Medical Officer C/O EFFECTOR THERAPEUTICS, INC., 142 NORTH CEDROS AVENUE, SUITE B, SOLANA BEACH CA 92075
Presidio Management Group X Llc 10 percent owner 2735 SAND HILL ROAD, MENLO PARK CA 94025
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Genesis Uk Llc 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004
Carlyle Investment Management Llc 10 percent owner 1001 PENNSYLVANIA AVE. N.W., WASHINGTON DC 20004
Carlyle Holdings I L.p. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Carlyle Holdings I Gp Inc. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Tc Group, Llc 10 percent owner C/O CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE NW SUITE 220 S, WASHINGTON DC 20004
Cg Subsidiary Holdings L.l.c. 10 percent owner C/O THE CARLYLE GROUP, SUITE 220 SOUTH, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004
Carlyle Holdings I Gp Sub L.l.c. 10 percent owner C/O THE CARLYLE GROUP L.P., 1001 PENNSYLVANIA AVENUE, NW, WASHINGTON DC 20004-2505
Gallagher Brian M. Jr. director, 10 percent owner C/O AILERON THERAPEUTICS, INC., 281 ALBANY STREET, CAMBRIDGE MA 02139
Stephen T Worland director, officer: President and Chief Executive 9050 CAMINO SANTA FE, SAN DIEGO CA 92121

eFFECTOR Therapeutics Headlines

From GuruFocus